Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Understanding CAPA in Clinical Trials: A Practical Guide for CRAs
Mohamad-Ali Salloum, PharmD • February 9, 2026
Share
Corrective and Preventive Action—better known as CAPA —is one of the most important quality tools in clinical research. If you work as a Clinical Research Associate (CRA), CAPA will appear frequently in monitoring visits, audit findings, inspection reports, protocol deviations, and site issues.
Yet most CRAs are never formally trained on how to manage CAPA effectively.
This guide breaks CAPA down into simple, human language, provides real‑world examples, and explains how to approach it as a CRA.
1. What Is CAPA?
Corrective Action
A corrective action is something you do to fix a problem that has already happened.
Example — Outdated ICF used
A site used an outdated version of the informed consent form (ICF). Corrective actions include:
- retrain staff,
- re‑consent all active participants using the correct ICF,
- update site tools.
Preventive Action
A preventive action is something you do to stop the problem from happening again in the future.
Example — Preventing ICF version errors
- add a checklist to verify the current ICF version before each visit,
- store only the current version in a restricted folder.
Reference:
ICH GCP E6(R2) Section 5.20 — root cause & corrective action.
FDA Quality System Regulation (21 CFR 820.100) — CAPA system requirements.
2. Why Does CAPA Matter to CRAs?
As a CRA, you are responsible for:
- identifying issues at the site
- assessing if a CAPA is needed
- ensuring the CAPA is realistic and effective
- following up to ensure implementation
- documenting actions in monitoring reports
CAPA ensures:
Patient safety
Data integrity
Protocol compliance
Inspection readiness
3. The CAPA Process — Simplified
1. Problem Identification
What exactly happened?
2. Containment
Immediate actions to control the damage.
3. Root Cause Analysis
Why did it happen?
- 5 Whys
- Fishbone/Ishikawa diagram
- Process mapping
4. Corrective Actions
5. Preventive Actions
6. Effectiveness Check
Did it work?
4. CAPA Examples and Case Scenarios for CRAs
Scenario 1: Missing Temperature Logs
Issue: Temperature logs were missing for 3 days.
Root cause: Study nurse was on emergency leave; no backup.
Corrective actions:
- Check current temperature & confirm no excursion.
- Retrain staff.
Preventive actions:
- Assign backup staff.
- Add reminders/alarms.
- Weekly PI/coordinator cross-check.
CRA follow‑up:
- Logs updated
- Backup trained
- Docs complete
Scenario 2: Visit Window Errors
Issue: Visits outside window.
Root cause: Manual calculations → errors.
Corrective actions:
- Recalculate all visit windows.
- Retrain coordinator.
Preventive actions:
- Validated visit window calculator.
- Checks in tracking logs.
Scenario 3: Missing ICF Signatures
Issue: Signatures missing on ICF pages.
Root cause: Staff rushing.
Corrective actions:
- Re-consent subjects.
- Retrain staff.
Preventive actions:
- Signature checklist.
- “Pending CRA review” ICF folder.
5. CRA Tips to Manage CAPA Effectively
✔ Ask the right questions
- “Walk me through the process.”
- “Who is responsible? What if absent?”
✔ Ensure realistic CAPA
CAPAs must be measurable, assignable, time-bound.
✔ Document everything
✔ Follow up every visit
✔ Focus on prevention, not blame
Goal: Find cause → Fix cause → Prevent recurrence.
6. Mini Quiz — Test Your Knowledge!
1.
Which describes a corrective action?
2.
A preventive action for visit window errors:
3.
Before corrective action comes:
4.
Wrong ICF version — root cause focuses on:
5.
CRA’s role in CAPA:
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Why does this always happen?
Discover the best ways to learn new skills
Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.